Ambit Biosciences Corp
AMBI
AMBI was delisted on the 10th of November, 2014.
0 hedge funds and large institutions have $0 invested in Ambit Biosciences Corp in 2014 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 48 closing their positions.
100% less funds holding
Funds holding: 49 → 0 (-49)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
100% less capital invested
Capital invested by funds: $154M → $0 (-$154M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 48
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCMI
Foresite Capital Management I
Larkspur,
California
|
-$32M |
| 2 |
AC
Aisling Capital
New York
|
-$25.4M |
| 3 |
O
OrbiMed
New York
|
-$23M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
-$16.8M |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$9.24M |
AMBI Hedge Fund Activity: Q4 2014 in Review
0 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in Ambit Biosciences Corp (AMBI) for Q4 2014, worth a combined $0 — down 100% from $154M a quarter earlier.
Sellers outnumbered buyers: 48 funds closed out of AMBI and 0 opened new positions — a net loss of 48 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Foresite Capital Management I, exiting entirely with an estimated $32M sold.
- 0 institutional investors held Ambit Biosciences Corp (AMBI) as of Q4 2014, down from 49 in Q3 2014.
- Funds reported $0 of Ambit Biosciences Corp stock for Q4 2014, down 100% quarter-over-quarter.
- 0 funds opened new Ambit Biosciences Corp positions in Q4 2014 and 48 closed out, a net change of -48 holders.
- The largest Ambit Biosciences Corp seller in Q4 2014 was Foresite Capital Management I, an estimated $32M sold.
Based on aggregated 13F filings for Q4 2014.